Maarten Van Roy
Impact in
-
- Monoclonal and Polyclonal Antibodies Research
- Immunology top 10%
- Immunotherapy and Immune Responses
Papers in
-
- interferon and immune responses 3
- Toxin Mechanisms and Immunotoxins 2
- Oncology 6
- HER2/EGFR in Cancer Research 2
- Peptidase Inhibition and Analysis 2
- Chemokine receptors and signaling 1
- Co-authors
- Tinneke Denayer (2 shared papers)Thomas Stöhr (1 shared paper)Hans Ulrichts (3 shared papers)Judith Baumeister (2 shared papers)Alex Hemeryck (2 shared papers)Joost A. Kolkman (1 shared paper)Sofie Poelmans (1 shared paper)Claude Libert (5 shared papers)
- Journals
- Annals of the Rheumatic Diseases (2 papers)Molecular Cancer Therapeutics (1 paper)Frontiers in Immunology (1 paper)Journal of Clinical Investigation (1 paper)Cancer Gene Therapy (1 paper)
- Partner nations
- BelgiumUnited KingdomNetherlands
In The Last Decade
Maarten Van Roy
16 papers receiving 837 citations
Maarten Van Roy's Hit Papers
Peers
Comparison fields: 5 of 105
- Radiology, Nuclear Medicine and Imaging 263
- Immunology 218
- Oncology 176
- Molecular Biology 344
- Hematology 55
Countries citing papers authored by Maarten Van Roy
This map shows the geographic impact of Maarten Van Roy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maarten Van Roy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maarten Van Roy more than expected).
Fields of papers citing papers by Maarten Van Roy
This network shows the impact of papers produced by Maarten Van Roy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maarten Van Roy. The network helps show where Maarten Van Roy may publish in the future.
Co-authors
The 25 scholars most cited alongside Maarten Van Roy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Animal models in translational medicine: Validation and prediction Hit paper breakdown → | 2014 | 324 |
| 2 | 2015 | 145 | |
| 3 | 2013 | 124 | |
| 4 | 2013 | 66 | |
| 5 | 2013 | 55 | |
| 6 | 2017 | 42 | |
| 7 | 2017 | 37 | |
| 8 | 2007 | 30 | |
| 9 | 2007 | 8 | |
| 10 | 2007 | 5 | |
| 11 | 2013 | 4 | |
| 12 | 2012 | 3 | |
| 13 | Triazene metabolism. VI. 3-Azidomethyl-3-alkyl-1-aryltriazenes, a new class of anti-tumour triazene with potential pro-drug applications. | 1987 | 3 |
| 14 | 2012 | 1 | |
| 15 | 2012 | 1 | |
| 16 | 2007 | 1 |
About Maarten Van Roy
Maarten Van Roy is a scholar working on Immunology, Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Cancer Research, having authored 16 papers that have together received 849 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (5 papers), interferon and immune responses (3 papers), Computational Drug Discovery Methods (2 papers), Toxin Mechanisms and Immunotoxins (2 papers), HER2/EGFR in Cancer Research (2 papers), Protease and Inhibitor Mechanisms (2 papers), Peptidase Inhibition and Analysis (2 papers) and Chemokine receptors and signaling (1 paper). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (263 citations), Immunology (218 citations), Oncology (176 citations), Molecular Biology (344 citations) and Hematology (55 citations). Maarten Van Roy has collaborated with scholars based in Belgium, United Kingdom and Netherlands. Frequent co-authors include Tinneke Denayer, Thomas Stöhr, Hans Ulrichts, Judith Baumeister, Alex Hemeryck, Joost A. Kolkman, Sofie Poelmans, Claude Libert, Cedric Ververken and Bert ’t Hart. Their work appears in journals such as Annals of the Rheumatic Diseases, Molecular Cancer Therapeutics, Frontiers in Immunology, Journal of Clinical Investigation and Cancer Gene Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.